drugset / Trial / NCT01446484

Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection

NCT01446484

RandomizedParallel-groupOpen-labelTreatment

Summary

T regulatory cells (T regs) are responsible for immune tolerance in solid organ transplant patients. This study will evaluate the treatment of children with kidney transplants either with Campath and other immune system suppressing medications alone or in combination with injection of autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells expanded ex vivo. The aim of this study is to develop a new strategy that will be more effective in preventing organ rejection and maintaining patient health.

Timeline

Start
2011-10
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CD4+CD25+CD127lowFoxP3+ T regulatory cells Cell therapy 2e+08 cells Subcutaneous
Background Alemtuzumab Monoclonal antibody Intravenous
Background Cyclosporine Peptide
Background Everolimus Small molecule Oral
Background Mycophenolate Mofetil Small molecule Oral
Background Sirolimus Small molecule Oral
Background Tacrolimus Small molecule